Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2022 - 11 - 14 tags : Treatment save search
ImmunoGen Announces FDA Accelerated Approval of ELAHERE™ (mirvetuximab soravtansine-gynx) for the Treatment of Platinum-Resistant Ovarian Cancer
Published: 2022-11-14 (Crawled : 23:00) - biospace.com/
IMGN | $31.23 0.03% 49M
|
Health Technology
|
| O: 0.0%
H: 9.24%
C: 7.46%
treatment fda approval cancer ovarian cancer
Lexicon’s LX9211 Shows Significant and Consistent Benefits in the Treatment of Painful Diabetic Neuropathy in Full Results From the Phase 2 RELIEF-DPN-1 Trial Presented at the 16th Annual Pain Therapeutics Summit
Published: 2022-11-14 (Crawled : 22:00) - globenewswire.com
LXRX | $1.87 -5.08% -5.07% 3.5M
|
Health Technology
|
| O: 3.43%
H: 2.07%
C: -3.73%
lx9211 treatment trial therapeutics results benefits diabetic
Nexalin Technology Announces Publication of a White Paper Validating its tACS Device for the Treatment of Generalized Anxiety Disorder
Published: 2022-11-14 (Crawled : 20:00) - globenewswire.com
NXL | $1.98 -13.54% -15.66% 370K
|
|
| O: -0.53%
H: 0.53%
C: -3.19%
treatment device technology publication
Therapeutic Solutions Announces Universal Donor Myeloid Derived Suppressor Therapy Platform for Treatment of Chronic Obstructive Pulmonary Disease (COPD)
Published: 2022-11-14 (Crawled : 19:00) - biospace.com/
TSOI | $0.0009 12.5% 0.0% 2.4M
|
Manufacturing
|
| O: 0.0%
H: 1.96%
C: 0.0%
treatment disease solutions universal therapy platform
Satsuma Pharmaceuticals Announces Topline Results from SUMMIT Phase 3 Trial of STS101 for the Acute Treatment of Migraine
Published: 2022-11-14 (Crawled : 12:00) - globenewswire.com
STSA | $1.1 -0.9% -0.91% 0
|
Health Technology
|
| O: -82.05%
H: 0.0%
C: 0.0%
sts101 treatment pharmaceuticals topline trial migraine
Eagle Pharmaceuticals Announces FDA Acceptance of Investigational New Drug Application for CAL02, a Novel First-in-Class Broad-Spectrum Anti-Virulence Agent for the Adjunct Treatment of Severe Community-Acquired Bacterial Pneumonia
Published: 2022-11-14 (Crawled : 12:00) - globenewswire.com
EGRX | $5.2 13.29% 12.24% 380K
|
Health Technology
|
| O: -0.59%
H: 1.61%
C: -1.87%
cal02 treatment fda pharmaceuticals drug application
Gainers vs Losers
| 46% | 54% |
Top 10 Gainers
KAVL | $6.3 135.96% 57.45% 44M
|
Wholesale Trade
PXMD | $0.74 79.7% 44.16% 4.5M
|
Health Technology
DYNT | $0.3704 -5.27% 43.09% 1.6M
|
Health Technology
LGVN P 3 d | $2.93 73.37% 42.52% 56M
|
HUBC | $1.95 50.0% 32.99% 73M
|
n/a
SPCB | $0.4004 45.07% 31.75% 130M
|
Electronic Technology
ONVO | $1.35 33.65% 24.62% 53M
|
Health Technology
OMQS | $0.7038 35.35% 24.3% 3.5M
|
Professional, Scientific, and T...
SNPO | $10.54 29.48% 22.88% 3.9M
|
EEIQ | $1.16 27.46% 20.86% 6.9K
|
Educational Services
Your saved searches
Save your searches and get alerts when important news are released.